Of the 24 deaths in placebo or lecanemab treatment groups across the Core + OLE, 3 were due to intracerebral hemorrhage: 1 placebo in the Core due to intracerebral hemorrhage (ICH), and 2 lecanemab in OLE with concurrent ICH (1 after tissue plasminogen activator [tPA] and 1 on anticoagulant therapy). The gene discussed is PLAT; the disease is intracerebral hemorrhage.